All In Biotech

Drug Trial Radar · NCT07349615

A Study of SHR-1918 In Participants With Hypertriglyceridemia

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hypertriglyceridemia

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 367 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

367

Actual

Start

Mar 31, 2026

Primary completion

Mar 2027

Study completion Oct 2027

Sponsor

Sponsor type
Industry
First posted
Jan 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypertriglyceridemia. The efficacy and safety of SHR-1918 will be evaluated after 24-weeks and 48-weeks treatment.

Conditions

  • Hypertriglyceridemia

Interventions

  • SHR-1918/ SHR-1918 placeboDrug

    SHR-1918/ SHR-1918 placebo Dose 1

  • SHR-1918/ SHR-1918 placeboDrug

    SHR-1918/ SHR-1918 placebo Dose 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in mean serum triglyceride (TG) levels at Week 20 and Week 24 relative to baselineTime frame: at 20 weeks and 24 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.